Down Syndrome - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 51 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Down Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Down Syndrome - Pipeline Review, H2 2014', provides an overview of the Down Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Down Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Down Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Down Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Down Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Down Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Down Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Down Syndrome - Overview 7
Pipeline Products for Down Syndrome - Comparative Analysis 8
Down Syndrome - Therapeutics under Development by Companies 9
Down Syndrome - Therapeutics under Investigation by Universities/Institutes 10
Down Syndrome - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Down Syndrome - Products under Development by Companies 13
Down Syndrome - Products under Investigation by Universities/Institutes 14
Down Syndrome - Companies Involved in Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
Eisai Co., Ltd. 16
Transition Therapeutics Inc. 17
AC Immune SA 18
NeuroNascent, Inc. 19
Selvita S.A 20
Down Syndrome - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ELND-005 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
donepezil hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RG-1662 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BTD-001 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ACI-24 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NNI-351 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SEL-141 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
APH-1104 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AVL-8168 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Down Syndrome - Recent Pipeline Updates 42
Down Syndrome - Discontinued Products 46
Down Syndrome - Product Development Milestones 47
Featured News & Press Releases 47
Apr 07, 2014: Transition Therapeutics Announces Development Update 47
Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome 48
Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome 48
Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome 49
Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Number of Products under Development for Down Syndrome, H2 2014 7
Number of Products under Development for Down Syndrome - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 15
Down Syndrome - Pipeline by Eisai Co., Ltd., H2 2014 16
Down Syndrome - Pipeline by Transition Therapeutics Inc., H2 2014 17
Down Syndrome - Pipeline by AC Immune SA, H2 2014 18
Down Syndrome - Pipeline by NeuroNascent, Inc., H2 2014 19
Down Syndrome - Pipeline by Selvita S.A, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Down Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 42
Down Syndrome - Discontinued Products, H2 2014 46